ASENSUS SURGICAL INC (ASXC)
US04367G1031 - Common Stock
Overall ASXC gets a fundamental rating of 3 out of 10. We evaluated ASXC against 195 industry peers in the Health Care Equipment & Supplies industry. While ASXC seems to be doing ok healthwise, there are quite some concerns on its profitability. ASXC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ASXC has reported negative net income.
In the past year ASXC has reported a negative cash flow from operations.
In the past 5 years ASXC always reported negative net income.
ASXC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ASXC's Return On Assets of -132.75% is on the low side compared to the rest of the industry. ASXC is outperformed by 89.23% of its industry peers.
With a Return On Equity value of -234.74%, ASXC is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -132.75% | ||
| ROE | -234.74% | ||
| ROIC | N/A |
ROA(3y)-77.11%
ROA(5y)-102.82%
ROE(3y)-115.84%
ROE(5y)-144.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASXC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASXC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASXC has been increased compared to 1 year ago.
ASXC has more shares outstanding than it did 5 years ago.
ASXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -24.52, we must say that ASXC is in the distress zone and has some risk of bankruptcy.
ASXC's Altman-Z score of -24.52 is on the low side compared to the rest of the industry. ASXC is outperformed by 88.72% of its industry peers.
There is no outstanding debt for ASXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.52 |
ROIC/WACCN/A
WACC10.08%
2.3 Liquidity
A Current Ratio of 2.88 indicates that ASXC has no problem at all paying its short term obligations.
ASXC has a Current ratio (2.88) which is in line with its industry peers.
ASXC has a Quick Ratio of 2.31. This indicates that ASXC is financially healthy and has no problem in meeting its short term obligations.
ASXC has a Quick ratio (2.31) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.31 |
3. Growth
3.1 Past
ASXC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.13%.
Looking at the last year, ASXC shows a very strong growth in Revenue. The Revenue has grown by 21.20%.
ASXC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.67% yearly.
EPS 1Y (TTM)3.13%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25%
Revenue 1Y (TTM)21.2%
Revenue growth 3Y39.2%
Revenue growth 5Y-18.67%
Revenue growth Q2Q120.77%
3.2 Future
ASXC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.73% yearly.
Based on estimates for the next years, ASXC will show a very strong growth in Revenue. The Revenue will grow by 79.22% on average per year.
EPS Next Y39.13%
EPS Next 2Y23.41%
EPS Next 3Y20.2%
EPS Next 5Y19.73%
Revenue Next Year46.38%
Revenue Next 2Y62.61%
Revenue Next 3Y82.88%
Revenue Next 5Y79.22%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ASXC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASXC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ASXC's earnings are expected to grow with 20.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.41%
EPS Next 3Y20.2%
5. Dividend
5.1 Amount
ASXC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASENSUS SURGICAL INC
NYSEARCA:ASXC (4/26/2024, 7:04:01 PM)
After market: 0.2567 +0.01 (+3.09%)0.249
+0.01 (+3.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap67.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -132.75% | ||
| ROE | -234.74% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)3.13%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y39.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.2%
Revenue growth 3Y39.2%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y